Evommune EVMN
NYSE EVMN
$8.64 +0.80 (+10.14%)
As of: Nov 11, 2026 · 3:59 PM EST

Evommune (EVMN) Total Current Liabilities (2024 - 2026)

Updated

Evommune (EVMN) recorded Total Current Liabilities of $17.49 million in Q2 2026, up 64.9% from the prior quarter.

Analysis

Evommune (EVMN) Total Current Liabilities (2024 - 2026) Analysis & Trends

At the end of FY2025, Evommune reported Total Current Liabilities of $17.91 million, down 36.0% from FY2024.

  • Across earlier years, Total Current Liabilities came in at $27.98 million in FY2024.
  • Quarterly Total Current Liabilities has ranged from $10.42 million in Q3 2025 to $27.98 million in Q4 2024 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $10.6 million (Q1 2026), $17.91 million (Q4 2025) and $10.42 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 47.00 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 55.46 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 43.10 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 28.80 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -31.27 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 23.23 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 12.00 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 31.73 Bn
10 Evommune 285.17 Mn -352.34 Mn - 17.49 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 17.49 Mn
Mar 31, 2026 10.60 Mn
Dec 31, 2025 17.91 Mn
Sep 30, 2025 10.42 Mn
Dec 31, 2024 27.98 Mn
API Access

Evommune Total Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-current-liabilities&ticker=EVMN&period=max&api_key=YOUR_API_KEY